Discovery and development of SAHA as an anticancer agent

Oncogene

Volumn 26, Issue 9, 2007, Pages 1351-1356

  Marks, P A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Apoptosis; Deacetylases; Histone deacetylase inhibitors; Histones

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CAPECITABINE; FLAVOPIRIDOL; FLUDARABINE; FLUOROURACIL; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; IMATINIB; ISOTRETINOIN; RETINOIC ACID; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VORINOSTAT;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CELL CYCLE ARREST; CELL DEATH; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL TRIAL; COLON CANCER; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DEHYDRATION; DIARRHEA; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROLEUKEMIA; FATIGUE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LARYNX CANCER; MESOTHELIOMA; METASTASIS; MONOTHERAPY; MULTIPLE MYELOMA; MYELOMA; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SOLID TUMOR; THYROID CANCER; UROGENITAL TRACT TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLINICAL TRIALS; DRUG DESIGN; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS;

MURINAE;

EID: 33847258674     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210204     Document Type: Review

References (50)

1. Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H et al. (1992). Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 80: 2604-2609.
2. Arner ES, Holmgren A. (2000). Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267: 6102-6109.
3. Bhalla KN. (2005). Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23: 3971-3993.
4. Breslow R, Jursic B, Yan ZF, Friedman E, Leng L, Ngo L et al. (1991). Potent cytodifferentiating agents related to hexamethylene bisacetamide. Proc Natl Acad Sci USA 88: 5542-5546.
5. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C et al. (2000). Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165-5170.
6. Butler LM, Zhou X, Xu W-S, Scher HI, Rifkind RA, Marks PA et al. (2002). The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99: 11700-11705.
7. Dokmanovic M, Marks PA. (2005). Prospects: Histone deacetylase inhibitors. J Cell Biochem 96: 293-304.
8. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA et al. (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193.
9. Friend C, Scher W, Holland JG, Sato T. (1971). Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci USA 68: 378-382.
10. Fuino L, Bali P,Wittmann S, Donapaty S, Guo F, Yamaguchi H et al. (2003). Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2: 971-984.
11. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. (2004). Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101: 1241-1246.
12. Haggerty TJ, Zeller KI, Osthus RC, Wonsey DR, Dang CV. (2003). A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. Proc Natl Acad Sci USA 100: 5313-5318.
13. Hail Jr N. (2005). Mitochondria: a novel target for the chemoprevention of cancer. Apoptosis 10: 687-705.
14. Hu E, DulE, Sung CM, Chen Z, Kirkpatrick R, Zhang GF et al. (2003). Identification of novelisoform-sel ective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307: 720-728.
15. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. (2005). Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71-76.
16. Johnstone RW, Licht JD. (2003). Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4: 13-18.
17. Kelly W, Marks P. (2005). Drug Insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clini Pract Oncol 2: 150-157.
18. Kelly WK, O'Connor OA, Krug L, Chiao J, Heaney M, Curley T et al. (2005). Phase I study of the oralhistone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), in patients with advanced cancer. J Clin Oncol 23: 3923-3931.
19. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W et al. (2003). Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9: 3578-3588.
20. Lehrmann H, Pritchard LL, Harel-Bellan A. (2002). Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 86: 41-65.
21. Li LCL-C, Carroll PRPR, Dahiya RR. (2005a). Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Nat Cancer Instit 97: 103.
22. Li X, Wong C, Mysel R, Slobodov G, Metwalli A, Kruska J et al. (2005b). Screening and identification of differentially expressed transcripts in circulating cells of prostate cancer patients using suppression subtractive hybridization. Mol Cancer 4: 30.
23. Mai A, Massa S, Pezzi R, Rotili D, Loidl P, Brosch G. (2003). Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J Med Chem 46: 4826-4829.
24. Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, Nebbioso A et al. (2005). Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem 48: 3344-3353.
25. Marks PA, Rifkind RA. (1978). Erythroleukemic differentiation. Annu Rev Biochem 47: 419-448.
26. Marks PA, Sheffery M, Rifkind RA. (1987). Induction of transformed cells to terminal differentiation and the modulation of gene expression. Cancer Res 47: 659-666.
27. McEleny KR, Watson RW, Coffey RN, O'Neill AJ, Fitzpatrick JM. (2002). Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate 51: 133-140.
28. Miller TA, Witter DJ, Belvedere S. (2003). Histone deacetylase inhibitors. J Med Chem 46: 5097-5116.
29. Minucci S, Pelicci PG. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
30. Olsen EO, Kim Y, Kuzel T, Pacheco T, Foss F, Parker S et al. (2006). Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): results of a phase IIb trial. Proceedings of the American Society for Clinical Oncology Abstract 7500. Vol. 24, No. 18S, June 20, 2006.
31. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA et al. (2005). Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 3697-3702.
32. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA et al. (2003). Novelmechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63: 4460-4471.
33. Powis G, Mustacich D, Coon A. (2000). The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 29: 312-322.
34. Reuben RC, Wife RL, Breslow R, Rifkind RA, Marks PA. (1976). A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc Natl Acad Sci USA 73: 862-866.
35. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA et al. (1998). A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95: 3003-3007.
36. Richon VM, Ramsay RG, Rifkind RA, Marks PA. (1989). Modulation of the c-myb, c-myc and p53 mRNA and protein levels during induced murine erythroleukemia cell differentiation. Oncogene 4: 165-173.
37. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. (2000). Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019.
38. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L et al. (1996). Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 93: 5705-5708.
39. Rosato RR, Almenara JA, Dai Y, Grant S. (2003a). Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2: 1273-1284.
40. Rosato RR, Almenara JA, Grant S. (2003b). The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63: 3637-3645.
41. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. (2006). Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 66: 1277-1281.
42. Shao Y, Gao Z, Marks PA, Jiang X. (2004). Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101: 18030-18035.
43. Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pienta KJ et al. (2005). Global gene expression profiling of circulating tumor cells. Cancer Res 65: 4993-4997.
44. Tanaka M, Levy J, Terada M, Breslow R, Rifkind RA, Marks PA. (1975). Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds. Proc Natl Acad Sci USA 72: 1003-1006.
45. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G et al. (2005). Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 673-678.
46. Waghray A, Schober M, Feroze F, Yao F, Virgin J, Chen YQ. (2001). Identification of differentially expressed genes by serial analysis of gene expression in human prostate cancer. Cancer Res 61: 4283-4286.
47. Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA. (2006). Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 103: 15540-15545.
48. Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U et al. (2005). A novelantisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 4: 1689-1698.
49. Yoo CB, Jones PA. (2006). Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50.
50. Yoshida M, Kijima M, Akita M, Beppu T. (1990). Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174-17179.